This webcast features: Kristin O’Neill, Principle Scientist, and William Tran, Sr. Bioprocess Engineer, Merck & Co., Inc., and Kevin Mullen, Senior Product Manager, Thermo Fisher Scientific As the demand for single-use technologies increases in terms of performance, efficiency, and ease-of-use, Thermo Fisher Scientific has introduced a next-generation bioreactor to the biopharma industry: The Thermo Scientific HyPerforma DynaDrive Single-Use Bioreactor (SUB). Building on our extensive experience, as well as nearly two decades of end-user feedback, the HyPerforma DynaDrive SUB employs a…
Tuesday, March 23, 2021 Daily Archives
Stirling Ultracold fifth acquisition in 2 years for BioLife
Supplier of services and bioproduction tools BioLife Solutions has merged with developer and manufacturer of ultra-low temperature freezers Stirling Ultracold. “We continue to execute on our M&A strategy with another acquisition that superbly complements our product portfolio. Combining Stirling’s -20°C to -86°C freezer systems with our liquid nitrogen products provides complete ultra-low temperature cold-chain infrastructure critical for personalized medicine,†said BioLife’s CEO, Mike Rice. The transaction is expected to close during the early second quarter of 2021 with BioLife planning…
WuXi Bio set for 430,000 L biomanufacturing capacity from 2024
The acquisition of CMAB Biopharma comes days after WuXi Biologics bought a Pfizer facility, months after it added a Bayer plant, and a decade after it entered the biomanufacturing space. Contract development and manufacturing organization (CDMO) is in the news again, just a week after it acquired a single-use biologics manufacturing plant in Hangzhou, China from Big Pharma firm Pfizer. This time it has entered an agreement to buy over 90% of fellow Chinese CDMO CMAB Biopharma for an undisclosed…